Introduction

The pandemic influenza A(H1N1)pdm09 virus was responsible for over 18,449 deaths worldwide from 2009 to 2010 [1]. Although increased mortality is generally associated with novel influenza viruses due to the lack of a preexisting immunity in the general population, several groups of patients at higher risk for complications due to the influenza infection were reinforced or sub-stratified by risky factors. The frequency of mixed population of virus, with more than one polymorphism at residue 222, was significantly higher in serious (10.6%) and fatal (46.7%) influenza cases, whereas those who showed mild influenza infections were all infected by D222 wild-type. Mixtures of quasi-species showed a significant association of mortality, especially for those with risk factors, in special pregnant women. These results not only reinforce the association between D222G substitution and influenza A(H1N1)pdm09-associated morbidity and mortality, but also add the perspective that a worse clinical prognosis is most likely correlated with mixtures of quasi-species at this HA residue. Therefore, quasi-species may have a critical and underestimated role in influenza-related clinical outcomes.
clinical outcomes of the Brazilian population. In our study, we found that A(H1N1)pdm09 mutants at any distribution at residue 222G/D/N are significantly associated with worse clinical conditions due to influenza and to risk factors than the D222G mutation alone. Moreover, we also found the heterogeneity of amino acids at residue 222 in a representative proportion of A(H1N1)pdm09-infected individuals in Brazil.

Materials and Methods

Data collection and ethical statement

Our laboratory is the National Reference Laboratory for influenza and Respiratory Diseases for the Brazilian Ministry of Health (MoH) and we also integrate the World Health Organization (WHO) network for Influenza surveillance, as a National Influenza Center (NIC). As part of these surveillance systems, we continuously receive samples of suspected cases for virological surveillance, which includes different laboratory testing, such as subtyping, antigenic and genetic analyses. Samples are collected from individuals with respiratory influenza-like illness or severe acute respiratory infection (SARI), according to WHO and MoH case definitions [8]. Sociodemographic, clinical and epidemiological data are also collected by the epidemiological surveillance teams in the different Brazilian states, which includes basic information, such as gender, age, city/state of case notification and residence and dates of symptoms onset and sample collection. Personal information such as name and address are confidential and only assessed by the head of Laboratory. At the entrance, samples and forms are coded, in such a way that all analyses remain anonymous for all staff (maintaining confidentiality, in accordance to our ethical protocol declared in the scope of our quality system; ISO 15189).

The majority of samples used in this investigation were collected during Influenza A(H1N1)pdm09 pandemics, a global public health emergency. After pandemics, virtually all samples were collected in the scope of the National Influenza Epidemiological Surveillance Program/MoH, as part of a global and federal public health policy for Influenza control and prevention. For the reasons stated above, a formal approval from our Ethical Committee is not required.

Patient and sample characteristics

We analyzed samples from 401 A(H1N1)pdm09-confirmed patients, as judged using the WHO/CDC RT-PCR protocol [8]. These samples were nasopharyngeal aspirates (NPAs) (n = 392) and lung tissue fragments (n = 9). Nine positive NPAs from 3 immunocompromised patients previously studied by our group and with prolonged viral shedding were also analyzed [9]. The samples were selected from our laboratory database. Clinical data from these patients were classified as follows: 1) fatal cases, individuals who died due to influenza-related complications; 2) serious infections, individuals with severe symptoms of respiratory infection, such as SARI, pneumonia or who underwent hospitalization due to influenza; 3) mild cases, from patients with no reports of any complications cited. Further classification of our patients was also used, based on comorbidities. These include the following categories: chronic pulmonary disorder, subjects with chronic obstructive pulmonary disease (COPD), asthma, chronic lung disease; immunosuppression, individuals with HIV, cancer and who underwent transplantation; metabolic disorder, diabetes, obesity and other disorders; cardiovascular disorder included those reporting hypertension group and chronic heart disease; and a group with any comorbidity was also considered. Subjects with incomplete clinical information were excluded from the classification as having mild, serious or fatal outcomes due to influenza infection. Nevertheless, if clinical information was incomplete, but data from risk factor available, such sample was included in the study.

RNA extraction, RT-PCR and Pyrosequencing (PSQ) assay

Viral RNA was extracted from NPAs using a QIAamp viral RNA mini kit (Qiagen, Hilden, Germany). Lung tissue fragments were macerated using a TissueRuptor (Qiagen), and RNA was extracted using an RNeasy mini kit (Qiagen). The RT-PCR protocol and PSQ assay were performed as described elsewhere [10]. For PSQ assay, customized dispersion order ATGTAT(-CAGT)6 was conducted in the PyroMark Q96 ID pyrosequencer (Qiagen) [10]. The analyses were performed based on the quality of the pyrograms and algorithm to calculate the proportion of each variant has been described elsewhere [10]. The PSQ protocol may allow for the detection of approximately 5.0% of the quasi-species. To be more conservative, we raised this cutoff by 50%. Thus, viral sub-populations with mixtures above 7.5% were considered in this study.

Statistical analyses

Descriptive and bivariate analyses (chi-square/Fisher’s exact test for categorical variables and t-test for means) were employed to assess putative associations between variables of interest and outcomes. Multiple logistic regressions were carried out, considering variables of epidemiological relevance and plausibility. Significance was set when \( p \) value <0.05. Analyses were performed using SPSS for windows, version 19 (SPSS Inc.).

Results

Associations among the heterogeneity of amino acids at residue 222 of the HA with epidemiological data and clinical outcomes

We focused in studying samples from the period when changes at 222 residue were more common in the literature, from 2009 to 2011 [11,12]. We performed PSQ analyses for 401 samples among these 70 samples presented any type of mutation in this residue, 9 (12.8%) were D222G alone and 61 (87.2%) were mixed viral populations. The presence of polymorphisms was significantly higher during the pandemic period (from April 2009 to August 2010), when compared to 2011 (Table 1). The large majority of the samples were collected from June to September/2009 (epidemiological weeks 26 to 35) and from May to August/2011 (epidemiological weeks 22 to 35) (Table 1) – which represents the autumn/winter in Brazil.

Although Brazil is a continental-wide country which crosses the equator line, all our samples were from its Southern Hemisphere portion. Samples from 4 out of the 5 regions of Brazil were studied, which includes the southern (56.6%), southeastern (37.4%), northeastern (3.3%) and northern (0.7%) regions. As most of the samples were collected in the southern and southeastern regions, where influenza A(H1N1)pdm09 activity was more intense [13], naturally the heterogeneity at HA residue 222 from samples of these regions were more frequent, ranging from 11 to 17% (Table 1). Although we found the higher frequency of quasi-species at 222 residue in northeastern region, the sampling of this region is very small, 21 specimens (Table 1). Besides, as our laboratory receives convenience samples, 12 out of these 21 cases were from patients that deceased and, therefore, were more likely to be infected with mutant viruses.

The mean age of the patients was 27.4 (± 18.2) years (ranging from 0 to 88 years old). There was no statistically significant
Prolonged viral shedding and mutants at residue 222

Because we have previously studied immunocompromised patients with prolonged A(H1N1)pdm09 shedding [9], we verified if mutant viruses and their sub-populations would emerge during the course of infection in these patients. We analyzed samples from patients with 9, 31 and 56 days of viral shedding. Positive correlation between mixed amino acid residues, a consequence of quasi-species emergence, with both serious infections and fatal outcomes (Table 1). Of note, and as mentioned above, our data are minimally biased by the use of 9 samples from the lower respiratory tract (lung tissues), which are richer in \( \alpha_2,3 \) and provide an environment more likely to allow the emergence of mutant viruses at the residue 222.

Impact of quasi-species at residue 222 in individuals with risk factors, especially pregnant women

Although studies on the D222G mutation have associated it with enhanced A(H1N1)pdm09-related morbidity and mortality [2] for the general population, information for risk categories remains scarce. We stratified our data to analyze putative associations between influenza-associated outcomes and heterogeneity at 222 residue in different risk exposure categories. Naturally, the stratification of our cases decreased the number of specimens studied in the different categories. Nevertheless, among individuals with any risk factor, only 16.0% (20/125) of subjects infected with D222 progressed to death whereas 51.7% (15/29) of those infected by 222G or mixed populations deceased (\( p<0.001 \)) (Table 2). Remarkably, similar finding were met among pregnant woman who deceased, where 20.5% and 61.5% had WT D222 and G or 222G progressed to death whereas 51.7% (15/29) of those infected by 222G or mixed populations deceased (\( p<0.001 \)) (Table 2).

Table 1. Sociodemographic, clinical and epidemiological characteristics according to Influenza A (H1N1)pdm09 HA 222 polymorphisms.

| Variables                  | N/Total (%) | Polymorphisms at 222 HA residue | \( p \) value* |
|----------------------------|-------------|---------------------------------|---------------|
|                            | D (WT)      | G                               | Mixed\(^1\)   |
| **Collection period**      |             |                                 |               |
| Pandemic period            | 301/401 (75.1) | 232/301 (77.1) | 8/301 (2.2) | 61/301 (15.2) |
| Post pandemic period       | 100/401 (24.9) | 99/100 (99.0) | 1/100 (1.0) | 0/100 (0.0) |
| **Geographical regions**   |             |                                 |               |
| South                      | 227/401 (56.6) | 197/227 (86.8) | 5/227 (2.2) | 25/227 (11.0) |
| Southeast                  | 150/401 (37.4) | 120/150 (80.0) | 4/150 (2.7) | 26/150 (17.3) |
| Northeast                  | 21/401 (5.3) | 11/21 (52.4) | 0/21 (0.0) | 10/21 (47.6) |
| North                      | 3/401 (0.7) | 3/3 (100.0) | 0/3 (0.0) | 0/3 (0.0) |
| **Gender**                 |             |                                 |               |
| Female                     | 221/401 (55.1) | 179/221 (81.0) | 6/221 (2.7) | 36/221 (16.3) |
| Male                       | 180/401 (44.9) | 152/180 (84.4) | 3/180 (1.7) | 25/180 (13.9) |
| **Origin of samples**      |             |                                 |               |
| Upper respiratory tract    | 392/401 (97.8) | 326/392 (83.2) | 9/392 (14.5) | 57/392 (14.5) |
| Lower respiratory tract    | 9/401 (2.2) | 5/9 (55.6) | 4/9 (44.4) | 0/9 (0.0) |
| **Clinical condition**     |             |                                 |               |
| Mild                       | 52/305 (17.0) | 52/52 (100.0) | 0/52 (0.0) | 0/52 (0.0) |
| Serious                    | 161/305 (52.8) | 140/161 (87.0) | 4/161 (2.5) | 17/161 (10.6) |
| Fatal                      | 92/305 (30.2) | 44/92 (47.8) | 5/92 (5.4) | 43/92 (46.7) |

WT, wild type D222; Pandemic period (EW 17/2009 to 9/2010); Post pandemic period (EW 22/2011 to 35/2011); Serious cases were defined as those who presented SARI or pneumonia and/or demanded hospitalization; EW, epidemiological week. \(^1\)G222 or mixed populations - regarded as the polymorphisms G/N; G/D; N/D or N/G/D at the 222 HA residue. *Associations were assessed by Pearson Chi-square tests and \( p \) value was considered significant when \( <0.05 \).

doi:10.1371/journal.pone.0092789.t001

Correlation between the emergence of quasi-species at influenza HA 222 residue with patient’s gender (Table 1). Although no statistical significance was observed for the heterogeneity at 222 residue of influenza HA with respect to the origin of the samples, the very small number of specimens analyzed from the lower respiratory tract may have impaired the statistics.

In virtually all cases of mild infection (n = 52), the wild-type (WT) D222 residue was present in the entire viral population (Table 1). Importantly, the frequency of WT D222 residue significantly diminished as influenza A(H1N1)pdm09-related illness severity increased – being observed in 87.0% and 47.8% of the patients with serious and fatal infections (Table 1), respectively. As previously published [14], our data reinforce a statistically significant association between the D222G mutation with serious and fatal outcomes (Table 1). Most importantly, we found a correlation between mixed amino acid residues, a consequence of quasi-species emergence, with both serious infections and fatal outcomes (Table 1). Of note, and as mentioned above, our data are minimally biased by the use of 9 samples from the lower respiratory tract (lung tissues), which are richer in \( \alpha_2,3 \) and provide an environment more likely to allow the emergence of mutant viruses at the residue 222.

Correlation between the emergence of quasi-species at influenza HA 222 residue with patient’s gender (Table 1). Although no statistical significance was observed for the heterogeneity at 222 residue of influenza HA with respect to the origin of the samples, the very small number of specimens analyzed from the lower respiratory tract may have impaired the statistics.

In virtually all cases of mild infection (n = 52), the wild-type (WT) D222 residue was present in the entire viral population (Table 1). Importantly, the frequency of WT D222 residue significantly diminished as influenza A(H1N1)pdm09-related illness severity increased – being observed in 87.0% and 47.8% of the patients with serious and fatal infections (Table 1), respectively. As previously published [14], our data reinforce a statistically significant association between the D222G mutation with serious and fatal outcomes (Table 1). Most importantly, we found a correlation between mixed amino acid residues, a consequence of quasi-species emergence, with both serious infections and fatal outcomes (Table 1). Of note, and as mentioned above, our data are minimally biased by the use of 9 samples from the lower respiratory tract (lung tissues), which are richer in \( \alpha_2,3 \) and provide an environment more likely to allow the emergence of mutant viruses at the residue 222.

mixtures containing WT and mutant viruses were found in NPAs. Interestingly, a large number of respiratory tract, potentially increasing the clinical severity of mutant viruses are also able to cause infection in the lower tropisms, as these viruses also bind a positive correlation with influenza-related severity. Although our data reinforce the association between the D222G mutation and mortality, our results also indicate that such an association is even stronger for mixtures of quasi-species. In addition, mixtures of quasi-species appear to have an important importance of quasi-species has been highlighted in the context of detection of diverse viral sub-populations and associations between quasi-species with influenza-related severity and fatality indicate the spread of viral replication throughout the respiratory tract. In other words, the emergence of quasi-species at residue 222 might be more dynamic during the course of influenza infection than the relatively stable detection of the completely changed D222G residue. In a lung autopsy sample from patient who died of viral pneumonia, viral sub-populations with 222D/G/N were found [17], as a high prevalence of polymorphisms at residue 222 were found in cases of fatal pneumonia, during the second wave of the A/H1N1)pdm09 pandemic in Mexico [11]. Thus, the combination of N222, G222 and D222 forming viral sub-populations may be critical, such as has been observed in the Americas where D222N variants were associated with mortality [21]. In accordance with these observations, mixed populations were found in 4 from 9 lung tissue samples from deceased subjects here analyzed [14,19]. Whereas other studies highlight that the most important change for morbidity and mortality in A/H1N1)pdm09 HA is the D222G mutation, we call special attention to the emergence of quasi-species and, thus, to other amino acid residues less well-associated with worse clinical outcomes. These differences may have occurred because we employed PSQ assays, which we believe lead to more precise results. Other reports on the role of D222G mutation in morbidity and mortality context are based in Sanger sequencing method [20,22,23,24,25,26], which is able to identify the predominant viral population. The use of PSQ, allowed us to explore the heterogeneity and contribution of other amino acid substitutions (and their combination) in clinical severity of disease, at the quasi-species level. In our study, 17.5% of the whole sample showed infection by HA-222 mutant viruses, from which G or mixed populations (D/G, G/N, D/N, D/G/N) were found in 12.8% and 87.2%, respectively. Those infected by a mutant virus/ mixed population were about 10 times more likely to die from Influenza A/H1N1)pdm09 infection than those infected by the WT virus (p<0.001). These results suggest that besides D222G, infections with mixed populations may be critical. Differences in the frequencies of quasi-species mixtures at residue 222 found by us and others [10,11,14,15,17] may be due to methodologies and/or to the characteristics of the samples that were analyzed in different countries, such as the abundance of specimens from the lower respiratory tract. In Brazil, we detected mixtures containing residue N222, which has been found and positively associated with influenza severity in other regions of the Americas [21].

### Discussion

Considering that the D222G polymorphism of the HA gene has been positively associated with disease severity [2,3] and that the importance of quasi-species has been highlighted in the context of this residue [11,14,15,16,17,18,19], in this study, we investigated whether any diversity of quasi-species at the 222 residue were associated with morbidity and mortality in Brazil, where about 10% of the global deaths by Influenza A/H1N1)pdm09 infections had occurred [13]. In addition, we also explored the role of comorbidities/underlying diseases in this context. Besides D222G, our results reinforce the importance of HA 222 mixed populations in disease severity and progression to death, especially among pregnant women.

It has been suggested that the sustained transmission of viral strains with the complete D222G mutation is virtually nonexistent [20]. Variants containing the G222 residue occur sporadically, and their presence does not contribute to the formation of phylogenetic groups [19]. In this study, mutants with the complete D222G mutation and different mixtures of quasi-species could be detected in specimens from severely ill and deceased patients. Although our data reinforce the association between the D222G mutation and mortality, our results also indicate that such an association is even stronger for mixtures of quasi-species. In addition, mixtures of quasi-species appear to have an important positive correlation with influenza-related severity.

Viral populations with residue D222 interact more efficiently with α2-6, whereas G222 and N222 strains have expanded tropisms, as these viruses also bind α2-3 [4,5]. Consequently, mutant viruses are also able to cause infection in the lower respiratory tract, potentially increasing the clinical severity of influenza infection [19,20]. Interestingly, a large number of mixtures containing WT and mutant viruses were found in NPAs. Because these are specimens from the upper respiratory tract, the

### Table 2. Distribution of polymorphisms at 222 HA residue in Influenza A(H1N1)pdm09 fatal cases, according to comorbidity or underlying disease.

| Risk factors                  | N fatal/ Total | Polymorphisms at 222 HA residue | p value* |
|------------------------------|----------------|---------------------------------|----------|
|                              |                | D      | G      | D/G    | N/D    | N/G    | N/G/D  | G or Mixed population |
| Any risk factor              | 35/154         | 20/125 | 3/6    | 1/9    | 1/2    | 3/3    | 7/9    | 15/29              | <0.001  |
| Pregnancy                    | 15/47          | 7/34   | 1/2    | 3/4    | 0/0    | 3/3    | 1/4    | 8/13               | 0.013   |
| Chronic cardiovascular disorder | 11/33         | 7/26   | 0/0    | 0/3    | 1/1    | 0/0    | 3/3    | 4/7               | 0.186   |
| Chronic pulmonary disorder   | 2/24           | 1/22   | 0/1    | 0/0    | 0/0    | 0/0    | 1/1    | 1/2              | 0.163   |
| Metabolic disorder           | 11/27          | 6/19   | 1/2    | 0/1    | 0/1    | 1/1    | 3/3    | 5/8               | 0.206   |
| Immunoedepression            | 5/33           | 4/29   | 0/0    | 1/3    | 0/0    | 0/0    | 0/1    | 1/4              | 0.500   |
| Tabagism                     | 5/20           | 4/16   | 1/2    | 0/1    | 0/0    | 0/0    | 0/1    | 1/4              | 1.00    |
| Chronic renal disorder       | 3/7            | 2/6    | 0/0    | 1/1    | 1/0    | 0/0    | 0/0    | 0/1              | 0.429   |

* Associations were assessed by Pearson Chi-square tests and p value was considered significant when <0.05.

doi:10.1371/journal.pone.0092789.t002
The identification of D222G viruses in mild cases [20,24] have been used to refute/abbreviate the importance of this mutation in disease severity [14,20]. In contrast to these studies, only WT viruses (D222G) were found among mild cases ($p<0.001$), emphasizing the relevant role of HA-222 mutations in the clinical outcome. This was particularly important among pregnant women – a population severely affected by the 2009 pandemic [27]. In this subsample, D222G and/or mixtures of quasi-species were significantly associated with death, suggesting that identification of mutant viruses may be an important proxy of clinical outcome. Increased levels of sialic acid and expression of sialic acid receptor linkage in respiratory tract have been described during pregnancy [28], what could possibly contribute to the selection of mutant viruses. In an experimental study, D222G mutant virus was also more virulent in pregnant mice [29]; however, mixtures of viruses representing heterogeneous compositions of amino acids at residue 222 were not used as a reference. For other exposure categories, composed of subjects with underlying chronic diseases (cardiovascular, renal, metabolic) or immunodepression, none association between clinical outcome and the presence of HA 222 mutations could be established. Maybe due to a lack of statistical power, since each of those strata was composed by a small subsample.

Finally, our work emphasize the emergence of mixtures of quasi-species at residue 222 in A(H1N1)pdm09 HA in Brazil, a country severely impacted by the 2009 pandemics. We not only reinforce the association of the D222G mutation with influenza severity and fatality but also add the perspective that a poor clinical prognosis is more strongly associated with mixtures of quasi-species at this residue. Therefore, heterogeneous quasi-species may have a critical and underestimated role in influenza-related clinical outcomes.

Author Contributions

Conceived and designed the experiments: PCR TMLS MMS. Performed the experiments: PCR TMLS. Analyzed the data: PCR FCM MLAO TMLS MMS. Contributed reagents/materials/analysis tools: TSG SBF ALFC MCDR MMS. Wrote the paper: PCR TMLS MMS.

References

1. World Health Organization (2010) Pandemic (H1N1) 2009 - update 112. Geneva. Available: http://www.who.int/csr/don/2010_08_06/en/index.html.
2. Cheng VC, To KK, Tse H, Hung IF, Yuen KY (2012) Two years after pandemic influenza A/2009/H1N1: what have we learned? Clin Microbiol Rev 25: 223-263.
3. World Health Organization (2010) Preliminary review of D222G amino acid substitution in the haemagglutinin of pandemic influenza A (H1N1) 2009 viruses. Wkly Epidemiol Rec 85: 21-28.
4. Chutinimitkul S, Herfst S, Strel J, Lowen AC, Ye J, et al. (2010) Virulence-associated substitution D222G in the hemagglutinin of 2009 pandemic influenza A(H1N1) virus affects receptor binding. J Virol 84: 11802-11813.
5. Liu Y, Childs RA, Matrosovich T, Wharton S, Palma AS, et al. (2010) Altered receptor specificity and cell tropism of D222G hemagglutinin mutants isolated from fatal cases of pandemic A(H1N1) 2009 influenza virus. J Virol 84: 12089-12094.
6. Beler JA, Jayaraman A, Raman R, Pappas C, Zeng H, et al. (2011) Effect of D222G Mutation in the Hemagglutinin Protein on Receptor Binding, Pathogenesis and Transmissibility of the 2009 Pandemic H1N1 Influenza Virus. PLoS One 6: e19989.
7. Lauring AS, Andino R (2010) Quasispecies theory and the behavior of RNA viruses. PLoS Pathog 6: e1001065.
8. WHO Global Influenza Network (2011) Manual for the laboratory diagnosis and virological surveillance of influenza. pp. 153.
9. Souza TM, Salluh JI, Bozza FA, Mesquita M, Soares M, et al. (2010) H1N1pdm influenza infection in hospitalized cancer patients: clinical evolution and viral analysis. PLoS One 5: e14138.
10. Levine M, Shou TG, Guoaceca LV, Mishin VP (2011) Detection of hemagglutinin variants of the pandemic influenza A (H1N1) 2009 virus by pyrosequencing. J Clin Microbiol 49: 1307-1312.
11. Vazquez-Perez JA, Iaa P, Kobasa D, Ormsby CE, Ramirez-Gonzalez JE, et al. (2013) A (H1N1)pdm09 HA D222 variants associated with severity and mortality in patients during a second wave in Mexico. Virol J 10: 41.
12. Yang M, Nakamura S, Daidoji T, Kawashita N, Takeshita M, et al. (2010) Frequency of D222G and Q223R hemagglutinin mutants of pandemic (H1N1) 2009 influenza virus in Japan between 2009 and 2010. PLoS One 7: e30946.
13. World Health Organization (2010) Pandemic (H1N1) 2009 - update 112. Geneva. Available: http://www.who.int/csr/don/2010_08_06/en/index.html.
14. Ministro da Saude (2010) Influenza Pandematica (H1N1) 2009 - Analise da situacao epidemiologica e da resposta no ano de 2009. In: Saude Selve, editor. Brasilia. pp. 21.
15. Wedel M, Walschina S, Wolf A, Schweiger B (2013) Predominance of HA-222/G Polymorphism in Influenza A(H1N1)pdm09 Viruses Associated with Fatal and Severe Outcomes Recently Circulating in Germany. PLoS One 8: e57039.
16. Wang B, Deyer DE, Seoljono M, Shi H, Mahtoo K, et al. (2011) Evidence of the circulation of pandemic influenza (H1N1) 2009 with D222G/N/S hemagglutinin polymorphisms during the first wave of the 2009 influenza pandemic. J Clin Virol.
17. Kuroda M, Katano H, Nakajima N, Tobiume M, Ainai A, et al. (2010) Characterization of quasispecies of pandemic 2009 influenza A virus (A/H1N1/2009) by de novo sequencing using a next-generation DNA sequencing. PLoS One 5: e10256.
18. Chen H, Wen X, To KK, Wang P, Tse H, et al. (2010) Quasi-species of the D222G substitution in the hemagglutinin of pandemic influenza A(H1N1) 2009 virus from patients with severe disease in Hong Kong, China. J Infect Dis 201: 1517-1521.
19. Rykkvin R, Klaaen A, Duthman S, Hungnes O (2013) Within-patient emergence of the influenza A(H1N1)pdm09 HA1 222G variant and clear association with severe disease, Norway. Euro Surveill 18.
20. Puzelli S, Facchini M, Spagnolo D, De Marco MA, Calzolotti L, et al. (2010) Transmission of hemagglutinin D222G mutant strain of pandemic (H1N1) 2009 virus. Emerg Infect Dis 16: 863-865.
21. Houng HS, Garner J, Zhou Y, Lyons A, Kuschner R, et al. (2012) Emergent 2009 influenza A/H1N1 viruses containing HA 2222 mutation associated with severe clinical outcomes in the Americas. J Clin Virol 53: 12-15.
22. Baldani F, Campanini G, Piralla A, Rovida F, Braschi A, et al. (2010) Severe outcome of influenza A/H1N1/09v infection associated with 2222G/N polymorphisms in the haemagglutinin: a multicentre study. Clin Microbiol Infect 17: 1166-1169.
23. Klaaen A, Rykkvin R, Duthman SG, Hungnes O (2010) Observed association between the HA1 mutation D222G in the 2009 pandemic influenza A/H1N1 virus and severe clinical outcome, Norway 2009-2010. Euro Surveill 15.
24. Ledesma J, Piao F, Ruiz MP, Navarro JM, Pinoiro L, et al. (2011) Substitutions in position 222 of haemagglutinin of pandemic influenza A (H1N1) 2009 viruses in Spain. J Clin Virol 51: 75-78.
25. Mak GC, Au KW, Tai LS, Chuang KC, Cheng KC, et al. (2010) Association of D222G substitution in haemagglutinin of 2009 pandemic influenza A (H1N1) with severe disease. Euro Surveill 15.
26. Miller RR, MacLean AR, Gunson RN, Carman WF (2010) Occurrence of haemagglutinin mutation D222G in pandemic influenza A (H1N1) infected patients in the West of Scotland, United Kingdom, 2009-10. Euro Surveill 15.
27. Mosby LG, Rasmussen SA, Jamieson DJ (2011) 2009 pandemic influenza A (H1N1) in pregnancy: a systematic review of the literature. Am J Obstet Gynecol 205: 10-18.
28. Orczyk-Pawilowicz M, Augustyniak D, Hirnle L, Katnik-Prastowska I (2012) Lectin-based analysis of fucose and sialic acid expressions on human amniotic IgA during normal pregnancy. Glycoconj J.
29. Chan KH, Zhang AJ, To KK, Chan CC, Poon VK, et al. (2010) Wild type and mutant 2009 pandemic influenza A (H1N1) viruses cause more severe disease and higher mortality in pregnant BALB/c mice. PLoS One 5: e13757.